<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704428</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1314-AS-102</org_study_id>
    <nct_id>NCT03704428</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of SHR1314 in axSpA</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, MAD Study to Evaluation of Safety, Tolerability and PK of SHR1314 With Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety, Tolerability and Pharmacokinetics&#xD;
      (PK) of SHR1314 with axial spondyloarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase I, multicenter, double-blind, randomized, placebo-controlled study. The&#xD;
      study originally planned to enroll 5 cohorts of 8 subjects each (N=40).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Actual">January 14, 2020</completion_date>
  <primary_completion_date type="Actual">January 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of multiple subcutaneous injections of SHR1314 in adult patients with axial spondyloarthritis 1.Incidence of Treatment-Emergent Adverse Events 2.Incidence of Injection site reaction</measure>
    <time_frame>Baseline to 169 days after dose administration</time_frame>
    <description>Safety and tolerability of multiple subcutaneous injections of SHR1314 assessed by adverse events and serious adverse events.&#xD;
Incidence of Treatment-Emergent Adverse Events&#xD;
Incidence of Injection site reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of SHR-1314</measure>
    <time_frame>Baseline to 169 days after dose administration</time_frame>
    <description>maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (tmax) of SHR-1314</measure>
    <time_frame>Baseline to 169 days after dose administration</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination half-life (t1/2) of SHR-1314</measure>
    <time_frame>Baseline to 169 days after dose administration</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of development of Anti-drug Antibodies (ADAs)</measure>
    <time_frame>Baseline to 169 days after dose administration</time_frame>
    <description>Incidence of development of Anti-drug Antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving an ASAS20 Response</measure>
    <time_frame>Week2, 4, 6, 8, 12,16</time_frame>
    <description>ASAS20 Response</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple subcutaneous injections of SHR-1314 dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple subcutaneous injections of SHR-1314 dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple subcutaneous injections of SHR-1314 dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple subcutaneous injections of SHR-1314 dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple subcutaneous injections of SHR-1314 dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1314</intervention_name>
    <description>Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of axial spondyloarthritis (axSpA) and fulfilling the 2009 ASAS&#xD;
             classification criteria.&#xD;
&#xD;
          2. Have a history of back pain ≥3 months with age at onset &lt;45 years.&#xD;
&#xD;
          3. Have active axSpA defined as BASDAI ≥4 at screening and baseline.&#xD;
&#xD;
          4. Have objective signs of inflammation by presence of elevated ESR and/or presence of&#xD;
             elevated CRP.&#xD;
&#xD;
          5. In the past had an inadequate response to at least 1 or 2 non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.&#xD;
&#xD;
          6. If taking NSAIDS be on stable dose for at least 2 weeks prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of ongoing, chronic or recurrent infectious disease or evidence of&#xD;
             tuberculosis infection.&#xD;
&#xD;
          2. Previous exposure to other biologic drug directly targeting Interleukin (IL)-17 or&#xD;
             Interleukin (IL)-17 receptor.&#xD;
&#xD;
          3. Total ankylosis of the spine.&#xD;
&#xD;
          4. Have recently received biologics, tumor necrosis factor inhibitors or other&#xD;
             immunomodulatory agents within 12 weeks.&#xD;
&#xD;
          5. Have either a current diagnosis or a recent history of malignant disease.&#xD;
&#xD;
          6. Are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Liberation Army General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jianwen Chen</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR1314</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

